These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 24329764)

  • 1. Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis.
    Bito T; Nishikawa R; Hatakeyama M; Kikusawa A; Kanki H; Nagai H; Sarayama Y; Ikeda T; Yoshizaki H; Seto H; Adachi A; Horikawa T; Oka M; Nishigori C
    Br J Dermatol; 2014 Apr; 170(4):922-9. PubMed ID: 24329764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antidrug antibodies in psoriasis: a systematic review.
    Hsu L; Snodgrass BT; Armstrong AW
    Br J Dermatol; 2014 Feb; 170(2):261-73. PubMed ID: 24117166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis.
    Takahashi H; Tsuji H; Ishida-Yamamoto A; Iizuka H
    J Dermatol; 2013 Jan; 40(1):39-42. PubMed ID: 23039179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of antibodies to anti-TNF agents in psoriatic patients: a preliminary study.
    Cozzani E; Burlando M; Parodi A
    G Ital Dermatol Venereol; 2013 Apr; 148(2):171-4. PubMed ID: 23588142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-adalimumab and anti-infliximab antibodies developed in psoriasis vulgaris patients reduced the efficacy of biologics: report of two cases.
    Matsumoto Y; Maeda T; Tsuboi R; Okubo Y
    J Dermatol; 2013 May; 40(5):389-92. PubMed ID: 23414225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)-α level and the efficacy of TNF-inhibitor therapy in psoriasis.
    Kui R; Gál B; Gaál M; Kiss M; Kemény L; Gyulai R
    J Dermatol; 2016 Sep; 43(9):1018-23. PubMed ID: 26892625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis.
    Lecluse LL; Driessen RJ; Spuls PI; de Jong EM; Stapel SO; van Doorn MB; Bos JD; Wolbink GJ
    Arch Dermatol; 2010 Feb; 146(2):127-32. PubMed ID: 20157022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: results in a single community-based hospital.
    Noda S; Mizuno K; Adachi M
    J Dermatol; 2012 Mar; 39(3):265-8. PubMed ID: 22126280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab.
    Yanai H; Lichtenstein L; Assa A; Mazor Y; Weiss B; Levine A; Ron Y; Kopylov U; Bujanover Y; Rosenbach Y; Ungar B; Eliakim R; Chowers Y; Shamir R; Fraser G; Dotan I; Ben-Horin S
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):522-530.e2. PubMed ID: 25066837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris.
    Gniadecki R; Bang B; Bryld LE; Iversen L; Lasthein S; Skov L
    Br J Dermatol; 2015 Jan; 172(1):244-52. PubMed ID: 25132294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study.
    Viguier M; Pagès C; Aubin F; Delaporte E; Descamps V; Lok C; Beylot-Barry M; Séneschal J; Dubertret L; Morand JJ; Dréno B; Bachelez H;
    Br J Dermatol; 2012 Aug; 167(2):417-23. PubMed ID: 22413927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up.
    Menting SP; van Lümig PP; de Vries AC; van den Reek JM; van der Kleij D; de Jong EM; Spuls PI; Lecluse LL
    JAMA Dermatol; 2014 Feb; 150(2):130-6. PubMed ID: 24352354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis.
    Reich K; Blauvelt A; Armstrong A; Langley RG; Fox T; Huang J; Papavassilis C; Liang E; Lloyd P; Bruin G
    Br J Dermatol; 2017 Mar; 176(3):752-758. PubMed ID: 27518376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction.
    Hoffmann JH; Hartmann M; Enk AH; Hadaschik EN
    Br J Dermatol; 2011 Dec; 165(6):1355-8. PubMed ID: 21801160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region.
    van Schie KA; Hart MH; de Groot ER; Kruithof S; Aarden LA; Wolbink GJ; Rispens T
    Ann Rheum Dis; 2015 Jan; 74(1):311-4. PubMed ID: 25342759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
    Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
    Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD.
    Ben-Horin S; Mazor Y; Yanai H; Ron Y; Kopylov U; Yavzori M; Picard O; Fudim E; Maor Y; Lahat A; Coscas D; Eliakim R; Dotan I; Chowers Y
    Aliment Pharmacol Ther; 2012 Mar; 35(6):714-22. PubMed ID: 22288419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis.
    Ferrándiz C; García A; Blasco AJ; Lázaro P
    J Eur Acad Dermatol Venereol; 2012 Jun; 26(6):768-77. PubMed ID: 22126264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of adalimumab on key drivers in the pathogenesis of psoriasis.
    Hendriks AG; van der Velden HM; Wolberink EA; Seyger MM; Schalkwijk J; Zeeuwen PL; de Jong EM; Pasch MC; van Erp PE; van de Kerkhof PC
    Br J Dermatol; 2014 Mar; 170(3):571-80. PubMed ID: 24640989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.
    Esposito M; Gisondi P; Cassano N; Ferrucci G; Del Giglio M; Loconsole F; Giunta A; Vena GA; Chimenti S; Girolomoni G
    Br J Dermatol; 2013 Sep; 169(3):666-72. PubMed ID: 23647206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.